AI Article Synopsis
- Coronary Slow Flow Phenomenon (CSFP) is a condition where coronary arteries show delayed blood flow even though they appear normal in angiograms; this study aimed to assess the impact of atorvastatin on left ventricular (LV) strain in CSFP patients.
- The study involved 51 patients receiving 40 mg of atorvastatin daily for eight weeks, with left ventricular function measured using echocardiograms before and after treatment.
- Results showed significant improvements in LV strain and function after atorvastatin treatment, but it did not significantly affect right ventricular function or pulmonary artery pressure.
Article Abstract
Background: Coronary Slow Flow Phenomenon (CSFP) is a well-recognized clinical entity characterized by delayed opacification of coronary arteries in the presence of a normal coronary angiogram. The objective of this study was determined and compared left ventricle (LV)strain in patients with CSFP before and after receiving a high-dose atorvastatin.
Materials And Methods: This cross-sectional study was conducted on 51 patients with CSFP from the beginning of 2021 to the end of September 2022. Trans-thoracic Echocardiogram (TTE) was performed by an echocardiography specialist. Thereafter, the patient's basic information was entered into the researcher's checklist after treatment with atorvastatin 40 mg daily for eight consecutive weeks. After eight weeks, the patients were subjected again to TTE. The data were analyzed in SPSS statistical software.
Results: The mean LV-GLS before taking atorvastatin was - 16.53%±3.63%. The mean LV-GLS after taking atorvastatin was 17.57%±3.53% (P.value = 0.01). The mean LV function before taking atorvastatin was 48.82%±9.19%. Meanwhile, the mean LV function after taking atorvastatin was 50.59%±7.91% (P = 0.01). There was no significantly change in left atrium volume (49.88 ± 0.68 vs. 49.9 + 0.67) after 8 weeks taking atorvastatin (P = 0.884).
Conclusion: The plasma ET-1 levels are elevated in CSFP patients, and atorvastatin improves coronary flow and endothelial function. As evidenced by the results of this study, the daily intake of 40 mg of oral atorvastatin during eight consecutive weeks in patients with CSFP significantly improved LV strain and LV function, however atorvastatin does not have a significant effect on improving the right ventricular function and pulmonary artery systolic pressure.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11429084 | PMC |
| http://dx.doi.org/10.1186/s12872-024-04198-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Investigating the relationship between opium use and coronary slow flow: a propensity score matched case-control study.
BMJ Open
December 2024
Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran (the Islamic Republic of).
Objectives: Recent studies have suggested a potential link between opium consumption and microvascular dysfunction in coronary arteries, which may contribute to the development of coronary slow-flow syndrome. This study aims to investigate the relationship between opium use and coronary slow-flow syndrome.
Design And Setting: This retrospective study analysed medical records of patients who underwent coronary angiography at the Tehran Heart Center from 2006 to 2020.
Association between inflammatory burden index and coronary slow flow phenomenon in patients with chest pain and no obstructive coronary arteries.
BMC Cardiovasc Disord
October 2024
Department of Cardiology, Shenzhen Luohu Hospital Group Luohu People's, Hospital The Third Affiliated Hospital of Shenzhen University, Shenzhen, China.
Article Synopsis
- The Inflammatory Burden Index (IBI) is a new indicator that shows the relationship between inflammation and various diseases, particularly coronary slow flow phenomenon (CSFP) in patients with chest pain but no obstructive coronary artery disease.
- In a study with 1,126 participants, it was found that IBI levels were significantly higher in patients with CSFP compared to those with normal blood flow, with IBI independently predicting CSFP alongside body mass index (BMI).
- The study concluded that IBI is a valuable tool for predicting CSFP, as it improves diagnostic accuracy with a specificity of 67.6% and sensitivity of 77.5% when levels exceed 15.74.
Effect of Ocular Perfusion Pressure on Incidence of Diabetic Retinopathy in Type 2 Diabetes: A Two-Year Prospective Study.
Transl Vis Sci Technol
October 2024
State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangdong Provincial Key Laboratory of Ophthalmology Visual Science, Guangdong Provincial Clinical Research Center for Ocular Diseases, Guangzhou, China.
Article Synopsis
- - This study aimed to explore the link between mean ocular perfusion pressure (MOPP), cerebrospinal fluid pressure (CSFP), and the occurrence of diabetic retinopathy (DR) in Southern Chinese individuals with type 2 diabetes (T2DM).
- - Conducted with 1,224 participants, the research involved measuring blood pressures and calculating MOPP and CSFP; results showed that higher MOPP is associated with an increased risk of DR incidence but not with its progression or regression.
- - The findings suggest that monitoring MOPP and blood pressure may help prevent or delay the onset of DR in T2DM patients, indicating MOPP could serve as a useful marker for detecting DR incidence.
Evaluation of changes in the global longitudinal strain for left ventricular function before and after eight weeks of taking high dose of atorvastatin in patients with coronary slow flow phenomenon.
BMC Cardiovasc Disord
September 2024
Department of Community Medicine, School of Medicine, Farshchian Cardiovascular Subspecialty Medical Center, Hamadan University of Medical Sciences, Hamadan, Iran.
Article Synopsis
- Coronary Slow Flow Phenomenon (CSFP) is a condition where coronary arteries show delayed blood flow even though they appear normal in angiograms; this study aimed to assess the impact of atorvastatin on left ventricular (LV) strain in CSFP patients.
- The study involved 51 patients receiving 40 mg of atorvastatin daily for eight weeks, with left ventricular function measured using echocardiograms before and after treatment.
- Results showed significant improvements in LV strain and function after atorvastatin treatment, but it did not significantly affect right ventricular function or pulmonary artery pressure.
Randomised Placebo-Controlled Pilot Trial Evaluating the Anti-Anginal Efficacy of Ticagrelor in Patients with Angina with Nonobstructive Coronary Arteries and Coronary Slow Flow Phenomenon.
J Clin Med
September 2024
School of Medicine, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, SA 5000, Australia.
: The coronary slow flow phenomenon (CSFP) is an angiographic finding characterised by the delayed passage of contrast through the coronary arteries, despite the absence of obstructive coronary artery disease (defined as less than 50% narrowing of the vessel lumen). Patients with the CSFP experience recurrent angina, for which there are limited evidence-based therapies. Ticagrelor may serve as an effective anti-anginal therapy for these patients by increasing adenosine levels, which could alleviate coronary microvascular dysfunction and its associated angina due to its vasodilatory properties.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!